2. Qin BD, Jiao XD , Yuan LY , et al.Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy. J Immunother Cancer. 2024 Apr 16;12(4):e008818. doi...
同时EGFR和KRAS突变,使用EGFR靶向药物、抗血管生成药物贝伐单抗、PD-1的纳武利尤单抗,有可能控制住病情,达到一个临床的获益。 参考文献:Wu CK,et al., Targeted Therapy and Immunotherapy Lead to Rapid Regression of Advanced Non-Small Cell Lung Cancer with Multiple Driver Mutations. J Thorac Oncol. 2018 J...
Pilotto S, Molina-Vila MA, Karachaliou N, et al. Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. Tr...
immunotherapyoncogenic-driverPD-1 inhibitorNon-small cell lung cancer (NSCLC) is a heterogeneous disease, commonly defined by genetic alterations in oncogenic drivers. Targeted therapies have transformed the management of oncogene-driven lung cancers, with targeted agents now approved in the United ...
医学评论英文版原文:Bruno D, Dowlati A. Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how? Transl Lung Cancer Res 2019;8(5):710-714. doi: 10.21037/tlcr.2019.06.02 被点评研究:Yang JC, Gadgeel SM, Sequist LV, et al. Pembrolizumab in Combination With Erlotinib ...
[1]H. Wang, Y. Zhang, Y. Xu, et al. Lung cancer scRNA-seq analyses reveal potential mechanisms causing different efficacy of target therapy and immunotherapy between EGFR 19del and L858R lung adenocarcinoma. ESMO 2024. Abstract 224P.
[1]Youn B, Trikalinos N A, Mor V, et al. Real‐world use and survival outcomes of immune checkpoint inhibitors in older adults with non–small cell lung cancer[J]. Cancer, 2019. [2]Guisier F, Dubos-Arvis C, Vias F, et al. Efficacy and safety of anti-PD-1 immunotherapy in patie...
Pilotto S, Molina-Vila MA, Karachaliou N, et al. Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. Transl Lung Cancer Res, 2015, 4(6): 721-727. doi: 10.3978/j.issn.2218...
4.Madeddu C,Donisi C,Liscia N,Lai E,Scartozzi M,MacciòA.EGFR-mutated non-small cell lung cancer and resistance to immunotherapy:role of the tumor microenvironment.Int J Mol Sci.2022;23(12):6489. 5.Nogami N,Barlesi F,Socinski MA,et al.IMpower150 final exploratory analyses for atezoli...
1. Gonzalo Pizarro et al. Case Report: Complete response to immunotherapy plus chemotherapy following an unusual clinical response to Afatinib and stereotactic radiosurgery in a metastatic EGFR-mutant NSCLC patient. Clinical Lung Cancer. 2020